Tom 19 (2024): Continuous Publishing
Artykuł przeglądowy
Opublikowany online: 2024-04-10
The vascular dose of rivaroxaban – still underutilized
DOI: 10.5603/fc.99672
Folia Cardiologica 2024;19.
Streszczenie
Brak
Referencje
- Mueck W, Stampfuss J, Kubitza D, et al. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013; 51(7): 549–561.
- Steffel J, Verhamme P, Potpara TS, et al. ESC Scientific Document Group, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330–1393.
- Spronk HMH, de Jong AM, Crijns HJ, et al. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res. 2014; 101(3): 344–351.
- Barylski M, Mamcarz A, Siebert J, et al. Nowy paradygmat leczenia przeciwzakrzepowego chorób miażdżycowych. Stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego dotyczące miejsca riwaroksabanu w terapii stabilnej choroby wieńcowej lub objawowej choroby tętnic obwodowych. Folia Cardiologica. 2019; 14(1): 30–45.
- Witkowski A, Barylski M, Filipiak KJ, et al. Zastosowanie leków przeciwkrzepliwych niebędących antagonistami witaminy K (NOAC) w leczeniu miażdżycy tętnic wieńcowych i obwodowych. Kardiol Pol. 2019; 1: 6–22.
- Bonaca MP, Creager MA, Olin J, et al. Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA 2°P-TIMI 50 trial. JACC Cardiovasc Interv. 2016; 9(20): 2157–2164.
- Grześk G, Koziński M, Navarese EP, et al. et al.. Kwas acetylosalicylowy – podstawa leczenia przeciwpłytkowego. Folia Cardiologica. 2011; 6(1): 49–61.
- Eikelboom J, Connolly S, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine. 2017; 377(14): 1319–1330.
- Connolly SJ, Eikelboom JW, Bosch J, et al. et al.. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double blind, placebo controlled trial. Lancet. 2018; 391(10117): 205–218.
- Anand SS, Bosch J, Eikelboom JW, et al. et al.. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double blind, placebo controlled trial, Lancet. 2018; 391(10117): 219–229.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348(9038): 1329–1339.
- Bhatt D, Fox K, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine. 2006; 354(16): 1706–1717.
- Morrow D, Braunwald E, Bonaca M, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Eng J Med. 2012; 366(15): 1404–1413.
- Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791–1800.
- Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002; 347(13): 969–974.
- Anand S, Yusuf S, Xie C, et al. Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007; 357(3): 217–227.
- Hiatt W, Fowkes F, Heizer G, et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. New England Journal of Medicine. 2017; 376(1): 32–40.
- Rogers RK, Herold J, Govsyeyev N, et al. VOYAGER PAD Committees and Investigators, executive committee of the VOYAGER PAD trial. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382(21): 1994–2004.
- Bauersachs RM, Szarek M, Brodmann M, et al. VOYAGER PAD Committees and Investigators. Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER pad trial. J Am Coll Cardiol. 2021; 78(4): 317–326.
- Capell WH, Bonaca MP, Nehler MR, et al. VOYAGER PAD Committees and Investigators, executive committee of the VOYAGER PAD trial, executive committee of the Voyager PAD trial. Rationale and design for the vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018; 199(21): 83–91.
- Visseren FLJ, Mach F, Smulders YM, et al. CAPTURE investigators, ESC Scientific Document Group, ESC Scientific Document Group, ESC Scientific Document Group, ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
- Chiarito M, Sanz-Sánchez J, Cannata F, et al. et al.. Monotherapy with a P2Y12 inhhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systemic review and meta-analysis. Lancet. 2020; 395(10235): 1487–1495.
- Frank U, Nikol S, Belch J, et al. ESVM Guideline on peripheral arterial disease, Vasa. 2019; 48(Suppl 102): 1–79.
- Jawień A, Filipiak K, Doroszko A, et al. Kompleksowa opieka nad pacjentem z chorobą naczyń obwodowych tętnic i żył — rekomendacje zespołu ekspertów 2023. Acta Angiologica. 2023; 29(2): 1–60.
- Mega J, Braunwald E, Wiviott S, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine. 2012; 366(1): 9–19.
